Prior studies have shown that FKBP5 is highly expressed across multiple tissues and significantly contributes to drug resistance in various cancers, including breast and prostate cancers, multiple myeloma, acute lymphoblastic leukemia, and melanoma (44). Here, FKBP5 is linked to plasma cell myeloma.